In type 2 diabetes, the impact of weight should be considered when choosing the most appropriate glucose-lowering therapies. GLP-1 RAs are more effective than DPP-4 inhibitors when weight loss or greater reductions in A1c are treatment priorities. GLP-1 RAs are effective at promoting weight loss by reducing appetite and feelings of hunger through inhibition of glucagon secretion and decreasing gastric emptying. Studies have shown that semaglutide and tirzepatide have very high efficacy for weight loss. Both long-acting and short-acting GLP RAs confer a similar weight loss benefit.
DPP-4 inhibitors are considered weight neutral agents.
Learn more about type 2 diabetes guidelines.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - Apr 28, 2023.